Screening for Hepatocellular Carcinoma: Recent Advances

Screening for Hepatocellular Carcinoma: Recent Advances

Structured Summary of Medical Lecture

1. Main Clinical Topics Discussed

• Global epidemiology and rising mortality trends of hepatocellular carcinoma (HCC)
• Identification of at-risk populations for HCC surveillance
• Evidence base and professional society guidelines supporting HCC surveillance programs
• Benefits and harms framework for HCC screening
• Current surveillance modalities and their limitations
• Emerging advances in HCC surveillance tools and biomarkers

2. Key Learning Points, Guidelines, and Recommendations

Epidemiology & Risk Stratification

• HCC is the third leading cause of cancer-related death worldwide
• Highest burden in East Asia and Africa, predominantly driven by endemic Hepatitis B
• Western countries show intermediate incidence but disturbing upward mortality trends
• HCC is projected to become the third leading cause of cancer-related death in the US by approximately 2035
• Rising proportion of HCC cases attributed to non-viral etiologies: non-alcoholic fatty liver disease (NAFLD/NASH) and alcohol-related liver disease
• Most HCCs arise in the setting of chronic liver disease or cirrhosis, providing a definable at-risk population
• Annual HCC risk in patients with cirrhosis: 1–3% per year
• Notable exception: Hepatitis B (DNA virus capable of integration) can cause HCC without cirrhosis; approximately 25–30% of NASH-related HCCs also appear to bypass the cirrhosis stage

Professional Society Guidelines

• AASLD, EASL, and APASL universally recommend HCC surveillance in high-risk individuals
• EASL: recommends ultrasound alone
• Asian guidelines (APASL): recommend ultrasound plus biomarkers (AFP, AFP-L3, DCP)
• AASLD (upcoming guidelines): moving toward ultrasound plus alpha-fetoprotein (AFP), aligning more closely with Asian recommendations

Prognosis by Stage — Rationale for Early Detection

• Early-stage HCC (BCLC 0/A): eligible for curative therapies (ablation, resection, transplantation); median survival >5–10 years
• Intermediate/Advanced stage (BCLC B/C): median survival 1.5–3 years despite therapeutic advances
• This differential in prognosis strongly justifies aggressive early detection programs

3. Specific Clinical Data, Statistics, and Study Results Cited

Landmark RCT (China — >18,000 patients)

• Only Level 1 evidence for HCC surveillance
• Patients randomized to surveillance vs. no surveillance
• Early detection rate: 60% vs. 0%
• Curative treatment rate: 47% vs. 8%
• HCC-related mortality reduction: 37%

Meta-analysis (Published in JHEP — Speaker's Group)

• HCC surveillance associated with:

- Improved early detection: OR ~1.9

- Increased curative treatment: OR ~1.8

- Reduced HCC-related mortality: HR 0.64

• Findings consistent across studies (confirmed by Forest plot)

Ultrasound Performance Data

• Pooled sensitivity of ultrasound for early-stage HCC detection: ~47% (range 21–89% across studies)
• ≥20% of ultrasound examinations are of suboptimal quality (classified as definitely or likely inadequate) — confirmed in a prospective study of 1,000 ultrasound exams independently reviewed by abdominal radiologists

HCC Surveillance Harms Data

• Only 4 studies to date, totaling ~2,500 patients — significant evidence gap
• Harms reported in 9–27% of surveillance encounters
• Harms characterized as mild in severity: primarily false positives requiring follow-up CT/MRI; few biopsies; rare hospitalizations
• No current data on financial or psychological harms (speaker's group to present preliminary data at upcoming AASLD meeting)

NAFLD-Related HCC Projections

• Modeling study projects continued increases in NAFLD-